Biocon Limited (BSE: 532523; NSE: BIOCON), a global biopharmaceutical company, has received approval from the United States Food and Drug Administration (US FDA) for Pebrilzo™ (pertuzumab-qcay), a biosimilar of Perjeta® (pertuzumab), used in the treatment of HER2-positive breast cancer. The approval marks another significant milestone in the company’s efforts to expand its oncology portfolio and increase the availability of high-quality biologic medicines.
Pebrilzo is a monoclonal antibody that targets HER2 receptors on cancer cells, helping address the growth and progression of HER2-positive breast cancer. The regulatory approval represents an important development in broadening treatment options for patients in the United States, subject to the anticipated commercial launch timeline.
With this approval, Pebrilzo becomes Biocon’s fifth oncology biosimilar approved by the US FDA, joining its existing portfolio of cancer therapies comprising Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb) and Aukelso® (denosumab-kyqq).
Commenting on the development, Shreehas Tambe, CEO and Managing Director, Biocon Limited, said the approval of Pebrilzo represented an important achievement in the company’s commitment to expanding access to quality biosimilar medicines. He highlighted the physical and financial challenges associated with HER2-positive breast cancer and noted that the addition of pertuzumab to the company’s oncology portfolio would further strengthen its efforts to make affordable biologic treatments accessible to patients.
The US approval follows a positive opinion issued in September by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorisation for Biocon’s pertuzumab biosimilar under the Pebrilzo brand. The recommendation covers the 420 mg/14 mL concentrate solution for infusion for the treatment of HER2-positive breast cancer across multiple disease stages in Europe.
The US FDA approval was supported by a comprehensive development package comprising structural and functional characterisation, analytical similarity assessments and comparative clinical pharmacokinetic data. These studies established that Pebrilzo is highly similar to the reference biologic, with no clinically meaningful differences in quality, safety, efficacy or immunogenicity. Biocon is also advancing its oncology development pipeline, which includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, covering HER2-targeted treatments and immuno-oncology.
HER2-positive breast cancer is characterised by overexpression of the HER2 protein or amplification of the HER2 gene, which can contribute to aggressive tumour growth. Approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026, with around 20% of cases classified as HER2-positive. The disease remains an important area of unmet medical need, highlighting the importance of expanding treatment options.
Biocon Limited is a global biopharmaceutical company headquartered in Bengaluru, India, focused on developing and delivering affordable medicines for patients worldwide. Its portfolio spans biosimilars and generics across major therapeutic areas, including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology and bone health.
The company has commercialised 12 biosimilar products and more than 30 generic formulations globally, supported by a development pipeline of over 20 biosimilar assets, GLP-1 peptides and complex generics. Operating in more than 120 countries, Biocon has seven manufacturing facilities, three research and development sites and 18 offices worldwide, supported by a workforce of over 9,500 employees. The company was included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year.